Outlook Therapeutics, Inc. current report, 17 June 2022

Abrir documento

Business Context and Reporting Period

Outlook Therapeutics, Inc. (OTLK), a Delaware corporation, filed this Current Report on Form 8-K on June 17, 2022. The filing addresses an amendment to an existing At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC.

Key Financial Metrics

This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The document focuses exclusively on capital raising activities.

  • ATM Program Capacity: The original agreement allowed for the sale of up to $40,000,000 of common stock.
  • Historical Proceeds: Since March 26, 2021, the Company has sold shares for aggregate gross proceeds of $14,143,920.
  • New Offering Capacity: Under the amended agreement and new prospectus supplement, the Company is offering shares with an aggregate offering price of up to $25,856,080.

Material Changes

The primary material change is the amendment to the ATM Agreement to expand the definition of "Registration Statement."

  • The Company replaced the expired "First Registration Statement" (File No. 333-231922) with a new shelf registration statement (File No. 333-254778) filed on March 26, 2021.
  • The Company has ceased using the First Registration Statement and will now conduct sales under the New Registration Statement and a related Prospectus Supplement filed on June 17, 2022.

Guidance, Outlook, and Risks

The filing contains no forward-looking guidance, management commentary on business operations, or specific risk factors beyond standard securities law disclaimers. The document notes that the report does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration.

Investor Verification Checklist

  • Verify the remaining capacity under the $40,000,000 ATM program after accounting for the $14,143,920 already raised.
  • Confirm the effectiveness of the new shelf registration statement (File No. 333-254778) with the SEC.
  • Review the attached Prospectus Supplement for specific terms regarding the $25,856,080 offering.
  • Check recent stock price trends to assess potential dilution from future sales under the ATM program.